Anbio Biotechnology
NNNN· Nasdaq
NNNNAnbio Biotechnology
Who holds Anbio Biotechnology, from the managers’ Form 13F reports for the quarter ended Jun 30, 2026.
Form 13F covers managers with $100 million or more. Positions are as of the quarter end and filed up to 45 days later; the latest quarter fills in as reports land.
| Manager | Shares | Change | Value | Of portfolio | Filed |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 26.7K | +3.8% | $366.6K | 0% | Aug 12, 2026 |
| Bank of America Corp | 13.4K | New | $184K | 0% | Aug 14, 2026 |
| BNP Paribas Financial Markets | 11.8K | +13.5% | $161.8K | 0.1% | Aug 13, 2026 |
| Marshall Wace, LLP | 11.5K | New | $157.7K | 0.1% | Aug 13, 2026 |
| Morgan Stanley | 7.2K | −1.5% | $99.1K | 0% | Aug 13, 2026 |
| UBS Group AG | 828 | −86.9% | $11.4K | 0% | Aug 13, 2026 |
| EverSource Wealth Advisors, LLC | 187 | −29.7% | $2.6K | 0.1% | Jul 24, 2026 |
| Osaic Holdings, Inc. | 77 | New | $1.1K | 0% | Aug 14, 2026 |
| JPMorgan Chase & Co | 53 | New | $718 | 0% | Aug 12, 2026 |
| Bare Financial Services, Inc | 15 | ±0% | $206 | 0% | Jul 27, 2026 |
| Larson Financial Group LLC | 5 | New | $69 | 0% | Aug 14, 2026 |
| Silver Grove Financial Group, Inc. | 4 | New | $55 | 0% | Aug 13, 2026 |
